{"hands_on_practices": [{"introduction": "A pathologist's assessment of prognostic markers often involves converting qualitative observations into a semi-quantitative score. This exercise [@problem_id:4438982] focuses on the Allred score for estrogen receptor (ER) status, a classic example of this process. You will practice calculating this score by combining proportion and intensity data, and then see how such a score becomes a powerful variable in a prognostic model to estimate a patient's risk of recurrence, bridging the gap between microscopic findings and quantitative risk assessment.", "problem": "A pathology laboratory reports immunohistochemistry (IHC) results for estrogen receptor (ER) in an invasive breast carcinoma. The ER staining shows a proportion of positively stained tumor nuclei of $40$ out of $100$ ($0.40$ as a fraction) and an average staining intensity judged by the pathologist as moderate. The patient has a primary tumor size of 2.3 centimeters, histologic grade of $2$ on the Nottingham scale, and a Ki-$67$ labeling index of 18 out of 100 nuclei ($0.18$ as a fraction). The axillary lymph nodes are negative, and the tumor is Human Epidermal Growth Factor Receptor 2 (HER2) negative. The patient receives adjuvant endocrine therapy alone.\n\nFrom fundamental definitions in pathology, the Allred score for ER is the sum of a proportion score and an intensity score. The proportion score is assigned as $0$ for $0$, $1$ for less than $0.01$, $2$ for $0.01$ to $0.10$, $3$ for $0.11$ to $0.33$, $4$ for $0.34$ to $0.66$, and $5$ for $0.67$ to $1.00$ fraction of positive tumor nuclei. The intensity score is assigned as $0$ for negative, $1$ for weak, $2$ for moderate, and $3$ for strong average staining intensity.\n\nA validated risk model for $10$-year distant recurrence under endocrine therapy in node-negative, HER2-negative disease uses a logistic regression of the form\n$$\np \\;=\\; \\frac{1}{1+\\exp\\!\\big(-\\big(\\alpha \\,+\\, \\beta_{s}\\,S \\,+\\, \\beta_{g}\\,G \\,+\\, \\beta_{k}\\,K \\,-\\, \\beta_{a}\\,A\\big)\\big)} \\,,\n$$\nwhere $p$ is the probability of distant recurrence by $10$ years, $S$ is tumor size in centimeters, $G$ is histologic grade as an integer from $1$ to $3$, $K$ is the Ki-$67$ fraction on the interval $[0,1]$, and $A$ is the ER Allred score. The coefficients are $\\alpha = -2.2$, $\\beta_{s} = 0.25$ per centimeter, $\\beta_{g} = 0.4$ per grade unit, $\\beta_{k} = 3.0$ per unit Ki-$67$ fraction, and $\\beta_{a} = 0.35$ per Allred point.\n\nRisk categories for distant recurrence are defined as follows: low risk if $p  0.10$, intermediate risk if $0.10 \\leq p  0.20$, and high risk if $p \\geq 0.20$. Using the provided data and these foundational definitions, compute the ER Allred score, then compute $p$ from the logistic model, and determine the risk category. Report only the calculated value of $p$ as a decimal, rounded to four significant figures. No units should be included in your reported value.", "solution": "The problem statement is first validated for scientific soundness, completeness, and objectivity.\n\n### Step 1: Extract Givens\n\nThe following data and definitions are provided in the problem statement:\n- ER proportion of positive tumor nuclei: $40$ out of $100$, equivalent to a fraction of $0.40$.\n- ER average staining intensity: moderate.\n- Primary tumor size ($S$): $2.3$ centimeters.\n- Histologic grade ($G$): $2$ on the Nottingham scale.\n- Ki-$67$ labeling index ($K$): $18$ out of $100$ nuclei, equivalent to a fraction of $0.18$.\n- Axillary lymph nodes: negative.\n- Human Epidermal Growth Factor Receptor 2 (HER2) status: negative.\n- Allred score definition: $A = (\\text{proportion score}) + (\\text{intensity score})$.\n- Proportion score mapping from fraction of positive nuclei:\n  - $0$: for $0$\n  - $1$: for Fraction $ 0.01$\n  - $2$: for $0.01 \\leq \\text{Fraction} \\leq 0.10$\n  - $3$: for $0.11 \\leq \\text{Fraction} \\leq 0.33$\n  - $4$: for $0.34 \\leq \\text{Fraction} \\leq 0.66$\n  - $5$: for $0.67 \\leq \\text{Fraction} \\leq 1.00$\n- Intensity score mapping from pathologist judgment:\n  - $0$: for negative\n  - $1$: for weak\n  - $2$: for moderate\n  - $3$: for strong\n- Logistic regression model for $10$-year distant recurrence probability ($p$):\n  $$p \\;=\\; \\frac{1}{1+\\exp\\!\\big(-\\big(\\alpha \\,+\\, \\beta_{s}\\,S \\,+\\, \\beta_{g}\\,G \\,+\\, \\beta_{k}\\,K \\,-\\, \\beta_{a}\\,A\\big)\\big)}$$\n- Model coefficients:\n  - $\\alpha = -2.2$\n  - $\\beta_{s} = 0.25$ per centimeter\n  - $\\beta_{g} = 0.4$ per grade unit\n  - $\\beta_{k} = 3.0$ per unit Ki-$67$ fraction\n  - $\\beta_{a} = 0.35$ per Allred point\n- Risk category definitions:\n  - Low risk: $p  0.10$\n  - Intermediate risk: $0.10 \\leq p  0.20$\n  - High risk: $p \\geq 0.20$\n- Required output: The value of $p$, rounded to four significant figures.\n\n### Step 2: Validate Using Extracted Givens\n\nThe problem is scientifically grounded, well-posed, and objective.\n- **Scientifically Grounded**: The problem is set within the established clinical and pathological context of breast cancer prognostication. The Allred score, Nottingham grade, Ki-$67$ index, and HER2 status are standard prognostic and predictive factors. The use of a logistic regression model is a standard biostatistical method for developing risk prediction tools. The model structure and variables are clinically relevant.\n- **Well-Posed**: The problem provides all necessary data, definitions, and a specific mathematical model to calculate a unique solution. The question is unambiguous and asks for a specific numerical output.\n- **Objective**: The problem is stated using precise, quantitative language and established clinical definitions. There are no subjective or opinion-based statements.\n\n### Step 3: Verdict and Action\n\nThe problem is deemed **valid**. A solution will be derived.\n\nThe solution proceeds in three steps: first, calculation of the ER Allred score; second, calculation of the probability of distant recurrence, $p$, using the provided logistic regression model; and third, determination of the risk category.\n\n**Step 1: Calculation of the ER Allred Score ($A$)**\n\nThe Allred score is the sum of a proportion score and an intensity score.\n\n- The proportion of positively stained nuclei is given as $0.40$. According to the provided scoring system, a fraction between $0.34$ and $0.66$ corresponds to a proportion score of $4$.\n- The staining intensity is described as \"moderate\". This corresponds to an intensity score of $2$.\n\nThe total Allred score ($A$) is the sum of these two scores:\n$$A = (\\text{proportion score}) + (\\text{intensity score}) = 4 + 2 = 6$$\n\n**Step 2: Calculation of the Probability of Distant Recurrence ($p$)**\n\nThe probability $p$ is calculated using the logistic regression model with the patient's specific data. The variables for the model are:\n- $S = 2.3$\n- $G = 2$\n- $K = 0.18$\n- $A = 6$\n\nThe coefficients are:\n- $\\alpha = -2.2$\n- $\\beta_{s} = 0.25$\n- $\\beta_{g} = 0.4$\n- $\\beta_{k} = 3.0$\n- $\\beta_{a} = 0.35$\n\nFirst, we compute the linear predictor, which is the argument of the exponential function, let's call it $L$:\n$$L = \\alpha \\,+\\, \\beta_{s}\\,S \\,+\\, \\beta_{g}\\,G \\,+\\, \\beta_{k}\\,K \\,-\\, \\beta_{a}\\,A$$\nSubstituting the values:\n$$L = -2.2 \\,+\\, (0.25)(2.3) \\,+\\, (0.4)(2) \\,+\\, (3.0)(0.18) \\,-\\, (0.35)(6)$$\n$$L = -2.2 \\,+\\, 0.575 \\,+\\, 0.8 \\,+\\, 0.54 \\,-\\, 2.1$$\n$$L = (-2.2 - 2.1) + (0.575 + 0.8 + 0.54)$$\n$$L = -4.3 + 1.915$$\n$$L = -2.385$$\n\nNow, we substitute $L$ back into the logistic function formula. Note the negative sign in the exponent.\n$$p = \\frac{1}{1+\\exp(-L)}$$\n$$p = \\frac{1}{1+\\exp(-(-2.385))}$$\n$$p = \\frac{1}{1+\\exp(2.385)}$$\n\nUsing the value of the exponential function, $\\exp(2.385) \\approx 10.859346$:\n$$p = \\frac{1}{1 + 10.859346}$$\n$$p = \\frac{1}{11.859346}$$\n$$p \\approx 0.0843216$$\n\nThe problem requires the answer to be rounded to four significant figures. The first four significant figures of $0.0843216$ are $8$, $4$, $3$, and $2$. The fifth significant digit is $1$, which is less than $5$, so we round down.\n$$p \\approx 0.08432$$\n\n**Step 3: Determination of the Risk Category**\n\nThe risk categories are defined as:\n- Low risk: $p  0.10$\n- Intermediate risk: $0.10 \\leq p  0.20$\n- High risk: $p \\geq 0.20$\n\nSince the calculated probability is $p \\approx 0.08432$, and $0.08432  0.10$, the patient falls into the **low risk** category. The problem asks to report only the value of $p$.", "answer": "$$\n\\boxed{0.08432}\n$$", "id": "4438982"}, {"introduction": "Modern cancer prognostication moves beyond anatomy alone by integrating a tumor's biological characteristics into the final stage. This practice problem [@problem_id:4439195] provides a direct application of the American Joint Committee on Cancer (AJCC) 8th Edition prognostic staging system for breast cancer. By working through a realistic clinical scenario, you will integrate the traditional anatomic stage ($TNM$) with histologic grade and biomarker status ($ER$, $PR$, $HER2$) to determine the definitive prognostic stage, illustrating how biology can significantly modify a patient's outlook and treatment plan.", "problem": "A patient presents with a newly diagnosed invasive breast carcinoma of no special type. Core biopsy shows a moderately differentiated tumor with a Nottingham histologic grade of $2$. Immunohistochemistry demonstrates Estrogen Receptor (ER) positivity and Progesterone Receptor (PR) positivity in the invasive component, and Human Epidermal Growth Factor Receptor 2 (HER2) is negative by both immunohistochemistry and in situ hybridization. On clinical work-up, the primary tumor measures 3.5 centimeters on imaging, corresponding to a primary tumor size category of $T_{2}$, there are $2$ clinically involved ipsilateral axillary lymph nodes confirmed by biopsy (corresponding to $N_{1}$), and no distant metastases are identified on staging studies (corresponding to $M_{0}$).\n\nUse the American Joint Committee on Cancer (AJCC) $8$th edition clinical prognostic staging system, which integrates the primary tumor category, regional lymph node status, distant metastasis status, histologic grade, and biomarker profile (ER, PR, HER2), to determine the clinical prognostic stage group for this tumor.\n\nTo express your answer as a single real number suitable for calculation, convert the stage group to an ordinal code using the following mapping:\n- Stage IA $\\rightarrow$ $1$\n- Stage IB $\\rightarrow$ $2$\n- Stage IIA $\\rightarrow$ $3$\n- Stage IIB $\\rightarrow$ $4$\n- Stage IIIA $\\rightarrow$ $5$\n- Stage IIIB $\\rightarrow$ $6$\n- Stage IIIC $\\rightarrow$ $7$\n- Stage IV $\\rightarrow$ $8$\n\nReport only the ordinal code as your final answer. No rounding is required. Do not include any units.", "solution": "The user has provided a clinical scenario and requested the determination of the American Joint Committee on Cancer (AJCC) 8th edition clinical prognostic stage group for a breast carcinoma, followed by a conversion of this stage group into a specified ordinal code.\n\n### Step 1: Problem Validation\n\nFirst, a critical validation of the problem statement is performed.\n\n**Extracted Givens:**\n*   **Tumor Characteristics:** Invasive breast carcinoma of no special type.\n*   **Histologic Grade:** Moderately differentiated, Nottingham histologic grade of $2$.\n*   **Biomarker Status:**\n    *   Estrogen Receptor (ER): Positive.\n    *   Progesterone Receptor (PR): Positive.\n    *   Human Epidermal Growth Factor Receptor 2 (HER2): Negative.\n*   **Anatomic Extent of Disease (TNM Classification):**\n    *   Primary Tumor (T): size $3.5$ centimeters, category $T_{2}$.\n    *   Regional Lymph Nodes (N): $2$ involved ipsilateral axillary nodes, category $N_{1}$.\n    *   Distant Metastasis (M): None identified, category $M_{0}$.\n*   **Staging System:** AJCC 8th edition clinical prognostic staging system.\n*   **Output Requirement:** An ordinal code based on the following mapping:\n    *   Stage IA $\\rightarrow$ $1$\n    *   Stage IB $\\rightarrow$ $2$\n    *   Stage IIA $\\rightarrow$ $3$\n    *   Stage IIB $\\rightarrow$ $4$\n    *   Stage IIIA $\\rightarrow$ $5$\n    *   Stage IIIB $\\rightarrow$ $6$\n    *   Stage IIIC $\\rightarrow$ $7$\n    *   Stage IV $\\rightarrow$ $8$\n\n**Validation Verdict:**\nThe problem is **valid**. It is scientifically grounded, using the standard, internationally recognized AJCC Cancer Staging Manual, 8th Edition. The provided clinical and pathological data are self-contained, consistent, and complete for the application of this staging system. The scenario is entirely plausible in a clinical setting. The question is well-posed, objective, and requires the application of a formal, algorithmic process, leading to a unique, verifiable solution.\n\n### Step 2: Solution Derivation\n\nThe AJCC 8th edition staging for breast cancer utilizes two systems: an anatomic stage group based solely on the TNM classification, and a more comprehensive clinical prognostic stage group that integrates the anatomic stage with key biological factors. The problem explicitly requires the use of the clinical prognostic stage.\n\nThe provided parameters are:\n*   $T$ category: $T_{2}$ (tumor size greater than $20$ mm but no more than $50$ mm)\n*   $N$ category: $N_{1}$ (metastases to $1$â€“$3$ axillary lymph nodes)\n*   $M$ category: $M_{0}$ (no distant metastases)\n*   Histologic Grade (G): $2$ (moderately differentiated)\n*   $ER$ Status: Positive\n*   $PR$ Status: Positive\n*   $HER2$ Status: Negative\n\nThe procedure is to first identify the anatomic stage and then use the prognostic factors to determine the final prognostic stage group.\n\n**1. Determine the Anatomic Stage Group:**\nThe anatomic stage is determined by the combination of $T$, $N$, and $M$ categories. For the given combination of $T_{2}N_{1}M_{0}$, the AJCC 8th edition Anatomic Stage Group is **Stage IIB**.\n\n**2. Determine the Clinical Prognostic Stage Group:**\nThe clinical prognostic stage integrates the anatomic stage with the tumor's biological profile. We must consult the AJCC 8th edition Prognostic Stage Group table for breast cancer, which stratifies patients based on the full set of parameters. We are looking for the entry corresponding to the patient's profile: $T_{2}$, $N_{1}$, $M_{0}$, Grade $2$, $ER$-Positive, $HER2$-Negative.\n\nAccording to the AJCC 8th Edition Clinical Prognostic Stage table:\n*   A tumor with anatomic stage components $T_{2}N_{1}M_{0}$ that is also $ER$-positive and $HER2$-negative is evaluated based on its histologic grade.\n*   For the combination of $T_{2}N_{1}$ ($M_0$), $ER$-positive, $HER2$-negative:\n    *   If Grade is $1$, the prognostic stage is Stage IB.\n    *   If Grade is $2$, the prognostic stage is **Stage IIA**.\n    *   If Grade is $3$, the prognostic stage is Stage IIA.\n\nThe patient's tumor is Grade $2$. Therefore, the correct Clinical Prognostic Stage Group is **Stage IIA**. This represents a down-staging from the anatomic stage of IIB, which reflects the more favorable prognosis of this biological subtype (hormone receptor-positive, $HER2$-negative) compared to what the tumor size and nodal involvement alone would suggest. The positive $PR$ status further supports the hormone receptor-positive classification but does not alter the stage assignment in this specific context.\n\n**3. Convert to Ordinal Code:**\nThe final step is to convert the determined stage group, Stage IIA, into the specified numerical code. The problem provides the mapping:\nStage IIA $\\rightarrow$ $3$.\n\nThus, the final answer is $3$.", "answer": "$$\\boxed{3}$$", "id": "4439195"}, {"introduction": "To precisely measure the impact of an individual prognostic factor while accounting for others, clinicians and researchers rely on multivariable statistical models. This exercise [@problem_id:4439104] delves into the interpretation of the Cox proportional hazards model, a cornerstone of modern survival analysis. You will learn how to translate the model's abstract regression coefficient, $\\beta$, for a finding like lymphovascular invasion (LVI) into a clinically meaningful hazard ratio ($HR$), providing a quantitative measure of its prognostic power.", "problem": "A pathology team is studying prognostic factors in invasive breast carcinoma and fits a multivariate Cox proportional hazards model to disease-specific survival. Lymphovascular invasion (LVI) is coded as a binary covariate where presence is $1$ and absence is $0$. The fitted model includes LVI and other covariates such as tumor size, histologic grade, and nodal status. Let the hazard at time $t$ given covariates be $h(t \\mid \\mathbf{X})$, and let the Cox model take the form $h(t \\mid \\mathbf{X}) = h_{0}(t)\\,\\exp(\\boldsymbol{\\beta}^{\\top}\\mathbf{X})$, where $h_{0}(t)$ is the baseline hazard and $\\boldsymbol{\\beta}$ are regression coefficients. The estimated coefficient for the LVI indicator is $\\beta_{\\text{LVI}}=0.45$, while all other covariates are held fixed.\n\nDefine the incremental hazard $\\Delta HR$ attributable to LVI as the proportional increase in hazard for a patient with LVI present relative to an otherwise identical patient without LVI, that is,\n$$\n\\Delta HR \\equiv \\frac{h(t \\mid \\text{LVI}=1,\\,\\mathbf{Z})}{h(t \\mid \\text{LVI}=0,\\,\\mathbf{Z})} - 1,\n$$\nwhere $\\mathbf{Z}$ denotes the vector of other covariates held fixed. Using only the definition of the Cox proportional hazards model and the definition of $\\Delta HR$ above, derive an expression for $\\Delta HR$ in terms of $\\beta_{\\text{LVI}}$, then evaluate it numerically for $\\beta_{\\text{LVI}}=0.45$. Round your final numerical answer to four significant figures. Express your answer as a pure number (no units).", "solution": "The user wants me to act as a meticulous STEM professor to validate and solve a problem in biostatistics concerning a Cox proportional hazards model.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n-   **Model:** Multivariate Cox proportional hazards model.\n-   **Hazard Function:** $h(t \\mid \\mathbf{X}) = h_{0}(t)\\,\\exp(\\boldsymbol{\\beta}^{\\top}\\mathbf{X})$.\n-   **Covariate:** Lymphovascular invasion (LVI) is a binary covariate, coded as $1$ for presence and $0$ for absence.\n-   **Covariate Vector:** The full vector of covariates is $\\mathbf{X}$, which includes LVI and other covariates $\\mathbf{Z}$ (e.g., tumor size, histologic grade, nodal status).\n-   **Coefficient:** The estimated coefficient for LVI is $\\beta_{\\text{LVI}}=0.45$.\n-   **Definition of Incremental Hazard:** The incremental hazard attributable to LVI, $\\Delta HR$, is defined as $\\Delta HR \\equiv \\frac{h(t \\mid \\text{LVI}=1,\\,\\mathbf{Z})}{h(t \\mid \\text{LVI}=0,\\,\\mathbf{Z})} - 1$, where $\\mathbf{Z}$ is held fixed.\n-   **Task:** Derive an expression for $\\Delta HR$ in terms of $\\beta_{\\text{LVI}}$, and then evaluate it numerically for $\\beta_{\\text{LVI}}=0.45$, rounding to four significant figures.\n\n**Step 2: Validate Using Extracted Givens**\n-   **Scientific Grounding:** The problem is firmly grounded in biostatistics and epidemiology. The Cox proportional hazards model is a standard, widely used method for survival analysis. The application to prognostic factors in breast cancer, such as LVI, is a canonical use case. The problem is scientifically sound.\n-   **Well-Posedness:** The problem is well-posed. It provides all necessary definitions and data ($\\beta_{\\text{LVI}}$, the model form, the definition of $\\Delta HR$) to derive a unique analytical expression and compute a unique numerical answer.\n-   **Objectivity:** The problem statement is written in precise, objective, and unbiased technical language.\n-   **Completeness and Consistency:** The problem is self-contained and internally consistent. The definition of $\\Delta HR$ is unambiguous and directly applicable to the provided model structure. There are no missing or contradictory pieces of information.\n-   **Realism:** The context and a coefficient value of $\\beta_{\\text{LVI}}=0.45$ (corresponding to a hazard ratio of $\\exp(0.45) \\approx 1.57$) are realistic for a significant prognostic factor in clinical oncology.\n\n**Step 3: Verdict and Action**\n-   **Verdict:** The problem is valid. It is a standard, well-posed problem in survival analysis.\n-   **Action:** Proceed with the solution.\n\n### Solution\n\nThe problem requires a derivation of the incremental hazard ratio, $\\Delta HR$, and its numerical evaluation. The starting point is the definition of the Cox proportional hazards model and the specific definition of $\\Delta HR$ provided.\n\nThe Cox proportional hazards model is given by:\n$$\nh(t \\mid \\mathbf{X}) = h_{0}(t)\\,\\exp(\\boldsymbol{\\beta}^{\\top}\\mathbf{X})\n$$\nwhere $h(t \\mid \\mathbf{X})$ is the hazard rate at time $t$ for a subject with a vector of covariates $\\mathbf{X}$, $h_{0}(t)$ is the baseline hazard function, and $\\boldsymbol{\\beta}$ is the vector of regression coefficients.\n\nThe vector of covariates $\\mathbf{X}$ can be partitioned to explicitly represent the LVI status and the vector of all other covariates, $\\mathbf{Z}$. The linear predictor term in the exponent, $\\boldsymbol{\\beta}^{\\top}\\mathbf{X}$, can thus be written as:\n$$\n\\boldsymbol{\\beta}^{\\top}\\mathbf{X} = \\beta_{\\text{LVI}} \\cdot (\\text{LVI}) + \\boldsymbol{\\beta}_{\\mathbf{Z}}^{\\top}\\mathbf{Z}\n$$\nwhere $\\text{LVI}$ is the binary variable ($1$ or $0$) and $\\boldsymbol{\\beta}_{\\mathbf{Z}}$ is the vector of coefficients for the other covariates $\\mathbf{Z}$.\n\nThe incremental hazard, $\\Delta HR$, is defined by comparing two patients who are identical except for their LVI status. Let's write the hazard functions for these two scenarios.\n\nFor a patient with LVI present ($\\text{LVI}=1$), the hazard function is:\n$$\nh(t \\mid \\text{LVI}=1,\\,\\mathbf{Z}) = h_{0}(t)\\,\\exp\\left(\\beta_{\\text{LVI}} \\cdot 1 + \\boldsymbol{\\beta}_{\\mathbf{Z}}^{\\top}\\mathbf{Z}\\right)\n$$\n\nFor an otherwise identical patient with LVI absent ($\\text{LVI}=0$), the hazard function is:\n$$\nh(t \\mid \\text{LVI}=0,\\,\\mathbf{Z}) = h_{0}(t)\\,\\exp\\left(\\beta_{\\text{LVI}} \\cdot 0 + \\boldsymbol{\\beta}_{\\mathbf{Z}}^{\\top}\\mathbf{Z}\\right) = h_{0}(t)\\,\\exp\\left(\\boldsymbol{\\beta}_{\\mathbf{Z}}^{\\top}\\mathbf{Z}\\right)\n$$\n\nNow, we substitute these expressions into the given definition of $\\Delta HR$:\n$$\n\\Delta HR = \\frac{h(t \\mid \\text{LVI}=1,\\,\\mathbf{Z})}{h(t \\mid \\text{LVI}=0,\\,\\mathbf{Z})} - 1 = \\frac{h_{0}(t)\\,\\exp\\left(\\beta_{\\text{LVI}} + \\boldsymbol{\\beta}_{\\mathbf{Z}}^{\\top}\\mathbf{Z}\\right)}{h_{0}(t)\\,\\exp\\left(\\boldsymbol{\\beta}_{\\mathbf{Z}}^{\\top}\\mathbf{Z}\\right)} - 1\n$$\n\nThe baseline hazard function $h_{0}(t)$ cancels from the numerator and the denominator. This is a direct consequence of the \"proportional hazards\" assumption, which implies that the ratio of the hazards for any two individuals is constant over time. The expression simplifies to:\n$$\n\\Delta HR = \\frac{\\exp\\left(\\beta_{\\text{LVI}} + \\boldsymbol{\\beta}_{\\mathbf{Z}}^{\\top}\\mathbf{Z}\\right)}{\\exp\\left(\\boldsymbol{\\beta}_{\\mathbf{Z}}^{\\top}\\mathbf{Z}\\right)} - 1\n$$\n\nUsing the property of exponential functions, $\\exp(a+b) / \\exp(b) = \\exp(a)$, we can further simplify the expression:\n$$\n\\Delta HR = \\exp(\\beta_{\\text{LVI}}) - 1\n$$\nThis is the derived analytical expression for $\\Delta HR$ in terms of $\\beta_{\\text{LVI}}$. This quantity represents the proportional increase in hazard associated with the presence of LVI, holding all other covariates constant. The term $\\exp(\\beta_{\\text{LVI}})$ is the hazard ratio (HR) for LVI.\n\nThe problem provides the numerical value for the coefficient, $\\beta_{\\text{LVI}} = 0.45$. We substitute this value into the derived expression to find the numerical value of $\\Delta HR$:\n$$\n\\Delta HR = \\exp(0.45) - 1\n$$\n\nUsing a calculator, we evaluate the expression:\n$$\n\\exp(0.45) \\approx 1.56831218549\n$$\n$$\n\\Delta HR \\approx 1.56831218549 - 1 = 0.56831218549\n$$\n\nThe problem requires rounding the final numerical answer to four significant figures. The first four significant figures of $0.56831218549$ are $5$, $6$, $8$, and $3$. The fifth significant figure is $1$, which is less than $5$, so we round down (truncate).\n\nTherefore, the numerical value of $\\Delta HR$ rounded to four significant figures is $0.5683$. This indicates that the presence of LVI is associated with an approximately $56.83\\%$ increase in the hazard of the event (disease-specific mortality) at any given time, compared to its absence, holding other factors constant.", "answer": "$$\n\\boxed{0.5683}\n$$", "id": "4439104"}]}